RAC

2.11%

$1.45 race oncology ltd

I don’t understand how the company can withhold positive or...

First 30 Last

Share
Profile

Follow
LifeStar

1,613 Posts.

271

26/06/23

18:56

Post #: 68478265
Share

Originally posted by KingBuzzo: ↑

RAC has dropped almost another 10% as of closing today (and more at at lows) since I posted this Wednesday (a mere 4 days ago!). The aussie dollar is also down 1.5% or so since then.

Fully diluted RAC market cap now sits barely above AUD 200 million / USD 133 million. Enterprise value now sits around AUD 180 million / USD 120 million.

I did a quick run through of the significant announcements and discoveries that have occurred in the more than 2.5 years since RAC was last at this valuation:
- positive Breast cancer pre-clinicals (including doxorubicin/cyclophosphamide/Zantrene 3 drug combo)
- positive Melanoma pre-clinicals (with both immunotherapy and kinase inhibitors)
- positive AML pre-clinicals
- positive ccRCC pre-clinicals
- positive Multiple Myeloma pre-clinicals
- Prof Chen joins SAB
- Second independent study confirming Bisantrene inhibits FTO
- SPP raises $29.7 million
- Sheba 2 AML Trial initiated and completed Phase 1 with 50% RR
- Additional patents granted
- FTO Biomarker study initiated
- Companion Diagnostic study initiated
- AML EMD Trial commenced
- Heart Protection discovery
- Independent confirmation in USA that bisantrene protects mouse hearts from doxorubicin toxicity
- New drug discovery program started
- IV Formulation announced (but GMP product not yet delivered)
- Buyback started, stalled and now completed
- Positive Pre-IND guidance received from FDA
- Cardioprotection Breast Cancer trial ethics approval received
- New cardioprotection study with Dr Brian Jensen started
- Cardioprotection market data released.
- Team of 10+ group of cardio-oncology Consultants/KOLs (USA and Australia) engaged to guide clinical development and commercial strategy
- Significant staffing changes - DCB in, DT out, PL and JC take the back seat, MH steps up, DF out, Advonate/AD/TH in, MR in.

Admittedly we're still waiting to know the full details of some of these announcements, but signs are that they are positive as we've been told that the data has been withheld for strategic/commercial reasons and/or to enable peer review and publishing in journals/conferences.

As the share price continues to drop, it seems that the market valuation is increasingly disconnected from the value of bisantrene as a drug and Race's internal IP and knowledge around FTO inhibition/mRNA epigenetics and Cardioprotection. I wonder if there is a price at which someone takes a swing at picking up the whole package? As I said last post, 5 years ago Merck paid USD 394 million for Cavatek, which has now been completely shelved. Race at current prices would seem like a much lower risk and potentially much higher reward purchase.

Expand

I don’t understand how the company can withhold positive or negative price sensitive information. They must release price sensitive information due to ASX disclosure rules.

RAC Price at posting: $1.16 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

First 30 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.45		Change 0.030(2.11%)		Mkt cap ! $247.1M

Open	High	Low	Value	Volume
$1.43	$1.45	$1.40	$163.8K	115.3K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$1.44

Sellers (Offers)

Price($)	Vol.	No.
$1.45	31396	1

View Market Depth

No.	Vol.	Price($)
1	500	1.440
1	11250	1.390
1	1000	1.380
1	5000	1.370
1	1279	1.365

Price($)	Vol.	No.
1.450	31396	1
1.480	3055	2
1.500	17040	2
1.520	6000	1
1.575	2000	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

RAC (ASX) Chart

I don’t understand how the company can withhold positive or...

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Cyclone signs MOU with Vale for development of Iron Bear play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I don’t understand how the company can withhold positive or...

Top Stories

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Cyclone signs MOU with Vale for development of Iron Bear play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News